Table 1 Patient characteristics at the time of histological diagnosis of NAFLD
Demographic data | |
|---|---|
Numbers of patients | 402 |
Gender, Male / Female, n | 245 / 157 |
Age, ya | 51 (20–87) |
Body mass index, kg/m2a | 26.1 (18.1–42.4) |
Presence of previous and current malignancy | |
None / Hepatocellular carcinoma / Other malignancy, n | 351 / 26 / 30 |
Type 2 diabetes mellitus, Absence / Presence, n | 276 / 126 |
Hypertension, Absence / Presence, n | 230 / 172 |
Hyperlipidemia, Absence / Presence, n | 274 / 128 |
Histological findings | |
Steatosis, 5–33% / > 33–66% / > 66%, n | 152 / 149 / 98 |
Lobular inflammation | |
No foci / < 2 foci / 2–4 foci / > 4 foci per 200× field, n | 28 / 242 / 116 / 13 |
Ballooning, None / Few cells / Many cells, n | 39 / 252 / 108 |
Stage, 0 / 1 / 2 / 3 / 4, n | 48 / 165 / 63 / 98 / 28 |
NAFLD activity score, ≤2 / 3, 4 / ≥5, n | 34 / 181 / 184 |
Diagnosis according to FLIP algorithm, NASH / non-NASH, n | 349 / 50 |
Laboratory dataa | |
Serum aspartate aminotransferase, IU/l | 44 (3–378) |
Serum alanine aminotransferase, IU/l | 69 (15–783) |
Gamma-glutamyl transpeptidase, IU/l | 72 (11–990) |
Platelet count, ×103/mm3 | 213 (40–471) |
Fasting plasma glucose, mg/dl | 101 (65–287) |
HbA1c, % | 5.9 (4.4–12.6) |
Uric acid, mg/dl | 5.9 (1.9–11.1) |
Total cholesterol, mg/dl | 204 (101–370) |
Triglycerides, mg/dl | 140 (31–1088) |
High-density lipoprotein cholesterol, mg/dl | 45 (14–85) |
Low-density lipoprotein cholesterol, mg/dl | 120 (27–243) |
Serum ferritin, μg/l | 227 (< 10–2067) |
High sensitive C-reactive protein, mg/dl | 0.095 (0.006–2.240) |
Alpha-fetoprotein, μg/l | 4 (1–10,930) |
PIVKA-II, AU/l | 18 (1–157,050) |